SCLN - noch einmal ein Rebound?! - 500 Beiträge pro Seite

[nkelchen]

ich bin zu 2,10$ rein -
aber erstmal nur mit 50% des geplanten Kapital.

nk

[nkelchen]

[posting]19.333.934 von nkelchen am 19.12.05 11:38:11[/posting]

Reuters.com - No Spin. No Agenda. Just the Facts. As they happen.

advertisement

SciClone says Hepatitis C drug fails to meet target in trials
Wed Dec 14, 2005 07:01 AM ET
Dec 14 (Reuters) - SciClone Pharmaceuticals Inc. (SCLN.O: Quote, Profile, Research) on Wednesday said its experimental drug Zadaxin to treat Hepatitis C infection did not show statistically significant results in a late-stage trial.
Zadaxin was, however, found effective in the treatment of malignant melanoma when administered in combination with dacarbazine chemotherapy in a mid-stage trial, the company said in a news release.

SciClone said Sigma-Tau S.P.A. was conducting mid-stage trials for the drug in Europe. (Reporting by Saumyadeb Chakrabarty in Bangalore)


© Reuters 2005. All Rights Reserved.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq and all other quotes delayed by at least 15 minutes. Reuters does not endorse the views or opinions given by any third party content provider.

[nkelchen]

[posting]19.334.011 von nkelchen am 19.12.05 11:44:00[/posting]

Die 2 ist wie Beton.
Das wird hier wieder ein Geduldsspiel...
nk

[nkelchen]

[posting]19.334.011 von nkelchen am 19.12.05 11:44:00[/posting]



nk

[nkelchen]

[posting]19.338.969 von nkelchen am 19.12.05 16:57:47[/posting]

TH 2,15 - na also!

nk

[h2o.0001]

Hi @ all, jetzt wird es wohl wieder nach oben gehen

[nkelchen]

2,38

nk

[nkelchen]

2,43!

nk

[nkelchen]

Die Ruhe vor dem Sturm?

Die 2,35 scheint gekonnt zugemauert zu sein..
aber wenn ich etwas habe, dann Zeit.

nk

[nkelchen]

Nachtrag:

12/20/2005 PAOLO CAVAZZA
Beneficial Owner of more than 10% of a Class of Security 34,642 SCLN Open Market Purchase
Cost $75,519.55


12/19/2005 PAOLO CAVAZZA
Beneficial Owner of more than 10% of a Class of Security 90,730 SCLN Open Market Purchase
Cost $181,163.00


nk

[nkelchen]

Der Block bei 2,20 ist weg -
könnte nun wieder Richtung 2,35 - 2,41 gehen..

[nkelchen]

nach bestandenem Test der 2€ Marke,
nun der Versuch über 2,50 zu kommen??



nk

[nkelchen]

[posting]19.920.842 von nkelchen am 27.01.06 22:46:05[/posting]

die 2,35 Marke wird permanent angeknabbert...
Würde die auf SK Basis gebreakt, wird ein neues
06erHoch möglich.

nk

[nkelchen]

[posting]19.997.535 von nkelchen am 01.02.06 18:53:46[/posting]

na wer sagt es denn:
ein neues *after desaster* Hoch bei 2,47!!
Heute noch über 2,50 schliessen und dann erst einmal
die Indikatoren abkühlen lassen...




nk

[nkelchen]

Press Release Source: SciClone Pharmaceuticals, Inc.


SciClone to Report Fourth Quarter and Year-End 2005 Results on March 1, 2006
Wednesday February 8, 6:30 am ET


SAN MATEO, CA--(MARKET WIRE)--Feb 8, 2006 -- SciClone Pharmaceuticals, Inc. (NasdaqNM:SCLN - News) today announced that it plans to report fourth quarter and year-end 2005 results and host a conference call on Wednesday, March 1, 2006.
The conference call will contain forward-looking statements. Financial and statistical information to be discussed on the call will be posted on the Investor Relations section of SciClone`s web site at www.sciclone.com prior to the commencement of the conference call.

DATE: Wednesday, March 1, 2006

TIME: 11:30 a.m. ET (8:30 a.m. PT)

WEBCAST: live call and replay accessible at http://www.sciclone.com

LIVE CALL: 877-502-9276 (U.S./Canada)
913-981-5591 (international)

REPLAY: 888-203-1112 (U.S./Canada)
719-457-0820 (international)
passcode: 4478213
ADVERTISEMENT


About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone`s lead product ZADAXIN® is currently being evaluated in late-stage clinical trials for the treatment of malignant melanoma and hepatitis C. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. SciClone`s strategy is to leverage its advantage in China by in-licensing or acquiring the marketing rights to other products to market in this rapidly growing pharmaceutical market. SciClone`s other drug development candidate is SCV-07, currently in early clinical development in the U.S. for the treatment of viral and other infectious diseases. For more information about SciClone, visit www.sciclone.com.



Contact:
Corporate information contact:
Becky Horner
Investor Relations
SciClone Pharmaceuticals, Inc.
650-358-3437



--------------------------------------------------------------------------------
Source: SciClone Pharmaceuticals, Inc.

[tupper]

Hallo, Onkelchen!
Sieht ja interessant aus und Paule kauft auch schon wieder.
Aber sollte man nicht die Zahlen am 1. März abwarten?
Was Gutes kann da eigentlich nicht kommen. Oder?

[nkelchen]

[posting]20.103.028 von tupper am 08.02.06 18:48:47[/posting]

Hallo Tupper -
ich fahre eine spezielle Strategie,
siehe Thread: Fragen & Antworten...........

Damit habe ich das Risiko eines grösseren draw downs
hoffentlich im Griff!

Gruss
nk

[tupper]

Den Thread lese ich aber nicht durch.
Ich vermute aber, dass du erst mal mit einer kleinen Position reingehst und bei einem weiteren Absturz kräftig nachkaufen willst.
Mich juckts eigentlich auch in den Fingern.
Paolo scheint der Sache aber auch nicht recht zu trauen, seine Käufe sind ja eher bescheiden.
Hast du dich mal mit den Fundamentals befasst oder spekulierst du nur auf den Chart?

mfg

[nkelchen]

[posting]20.103.613 von tupper am 08.02.06 19:15:18[/posting]

Schau dir einfach ein wöchentliches Update des Depots im verlinkten Thread an.

Da reicht ein Posting - und es dürfte so fast alles erklärt sein...

Gruss
nk

[tupper]

So, ich bin dabei!

[nkelchen]

[posting]20.122.712 von tupper am 09.02.06 18:58:12[/posting]

schön,
dürfte noch einige Tage dümpeln, ehe wir die 2,50 antesten werden...

nk

[tupper]

Ich hab Zeit.
In ein bis zwei Jahren sehen wir irgendwann mindestens die 5$.

Die Fundamentals sind übrigens so schlecht nicht. Ca. 1$ ist schon alleine durch das Eigenkapital gedeckt.

mfg

[nkelchen]

[posting]20.136.836 von tupper am 10.02.06 15:34:14[/posting]

Ja aber Vorsicht -
diese Biotech Buden verbrennen jedes Quartal eine Menge Kohle....

nk

[tupper]

Dafür sind aber eventuelle Patente bzw. der Wert der bisherigen Forschungen nicht bilanziert.
Und Paule will sicher sein Geld wieder!!

[nkelchen]

[posting]20.138.291 von tupper am 10.02.06 16:48:41[/posting]

SciClone Pharma quarterly loss narrows, sales rise

(6:42 AM ET) LONDON (MarketWatch) -- SciClone Pharmaceuticals, Inc.(SCLN)posted a fourth-quarter net loss that narrowed to $1.6 million, or 4 cents a share, from $2.4 million, or 5 cents a share, in the year-earlier period. Revenue rose to $7.4 million from $6.1 million on a 22% jump in sales of Zadaxin, SciClone`s lead product. The company predicted Zadaxin sales will rise to about $32 million in 2006, driven by continued growth in China. Net loss in 2006 is estimated at about 13 cents a share.

[nkelchen]

[posting]20.442.613 von nkelchen am 01.03.06 14:23:56[/posting]

Neues AD Hoch bei 2,51 !!

Das könnte der Anfang eines schönen Rebounds sein...

nk

[nkelchen]

[posting]20.444.557 von nkelchen am 01.03.06 15:42:29[/posting]


nk

[tupper]

schöön...schöön...schööön!

Schaun mer mal!

[nkelchen]

die 2,50 muss halten, dann geht es über die 3..



nk

[tupper]

2,50 hält locker. Unterstützung schon bei ca. 2,60.
Ein Falsebreak ist natürlich immer drin.
Wenn die nächsten Testergebnisse (April, Mai?) keine bösen Überraschungen bringen, dürfen wir uns schon früher freuen als geplant.

[tupper]

Die geht ja ab wie Nachbars Lumpi!

[nkelchen]

[posting]20.741.414 von tupper am 16.03.06 19:59:56[/posting]

Hallo tupper,
so soll es sein...

Gruss
nk

[tupper]

Ich glaube, die läuft ziemlich glatt durch. Traden lohnt wohl nicht, zumindest mal bis 3,50. Dann muss man die Lage neu peilen.
Siehst du irgendwo, ob da noch Shorties drin sind?

[nkelchen]

SciClone gets U.S. FDA orphan drug designation
Mon Mar 20, 2006 6:47 AM ET
Printer Friendly | Email Article | Reprints | RSS

NEW YORK, March 20 (Reuters) - SciClone Pharmaceuticals Inc. (SCLN.O: Quote, Profile, Research) on Monday said thymalfasin, the chemical composition of Zadaxin, received an orphan drug designation for malignant melanoma from the U.S. Food and Drug Administration.

The company said it expected to report additional tumor response data and preliminary survival information from this trial later in 2006.



© Reuters 2006. All Rights Reserved.

[tupper]

...und unser Paule hat auch wieder schön eingekauft (z. B. 14.3. zu 2,50$).

[nkelchen]

Antwort auf Beitrag Nr.: 20.872.098 von tupper am 20.03.06 17:13:08

Neues aD high bei 3,60!!!



SciClone Reveals Positive Data From Phase 2 Liver Cancer Trial - Quick Facts

Monday, March 27, 2006; Posted: 06:52 AM

Find out where SCLN is going
Use our most popular trading tool to find
out how SCLN will move in the next
5 days.




Stocks rated 9 and 10 have outperformed the average stock by approximately 14 to 1 since 1995 and ideally are the stocks to focus on each day. Stocks rated 1 and 2 on average have lost money and you want to know these stocks in order to avoid them.

Click here for more details



(RTTNews) - SciClone Pharmaceuticals, Inc. (SCLN | charts | news | Powerrating) reported positive data from its phase 2 hepatocellular carcinoma, or primary liver cancer, trial.

SciClone noted that these data in late 2005, which showed a median survival of 994 days for the 12 patients who received ZADAXIN plus trans-arterial chemoembolization (TACE | charts | news | Powerrating), compared with a median survival of only 399 days for the 13 patients who only received TACE. A positive trend in median survival was observed for patients who received ZADAXIN plus TACE, compared with patients who only received TACE, the company said.

Copyright(c) 2006 RealTimeTraders.com, Inc. All Rights Reserved

[tupper]

Antwort auf Beitrag Nr.: 20.964.057 von nkelchen am 27.03.06 19:06:19

Die nächste harte Nuss dürfte bei 4,00 liegen. Bis dahin bleibe ich auf jeden Fall dabei.

[nkelchen]

Antwort auf Beitrag Nr.: 20.965.293 von tupper am 27.03.06 20:19:32

--------------------------------------------------------------------------------



SciClone Announces Settlement of Schering Plough KK (SPKK) Dispute
SAN MATEO, CA -- (MARKET WIRE) -- 04/03/2006 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it has reached a settlement in its dispute with SPKK concerning clinical trials conducted in Japan with ZADAXIN®, SciClone's lead compound. Under this resolution, SciClone will receive $8,000,000 from SPKK.

"We are pleased to reach a mutually acceptable resolution to our past differences, and we believe that the settlement is fair," stated Dr. Ira Lawrence, President and Chief Executive Officer of SciClone Pharmaceuticals, Inc. "Moving forward at SciClone, we plan to consider the option of pursuing further clinical development in Japan with ZADAXIN, although our immediate focus for ZADAXIN remains on the pursuit of regulatory approvals in the United States and Europe."

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN is currently being evaluated in late-stage clinical trials for the treatment of malignant melanoma and hepatitis C. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. SciClone's strategy is to leverage its advantage in China by in-licensing or acquiring the marketing rights to other products to market in this rapidly growing pharmaceutical market. SciClone's other drug development candidate is SCV-07, currently in early clinical development in the U.S. for the treatment of viral and other infectious diseases. For more information about SciClone, visit www.sciclone.com.

The information in this press release contains forward-looking statements including our expectations and beliefs regarding progress and results of our clinical trials. Words such as "expects," "plans," "believe," "may," "will," "anticipated," "intended" and variations of these words or similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, goals, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, including changes in demand for ZADAXIN, the progress or failure of clinical trials, our actual experience in executing on our objectives, the performance of our partners, maintenance of the sufficiency and eligibility of the enrolled patient population, unanticipated delays or additional expenses incurred during our clinical trials, our future cash requirements, delays in analyzing and synthesizing data obtained from clinical trials, future actions of our strategic partners, unexpected delays in preparation for enrollment, future actions by the U.S. Food and Drug Administration or equivalent regulatory authorities in Europe and the fact that experimental data and clinical results derived from studies with a limited group of patients may not be predictive of the results of larger studies, as well as other risks and uncertainties described in SciClone's filings with the Securities and Exchange Commission.






--------------------------------------------------------------------------------


Corporate information contact:
Becky Horner
Investor Relations
SciClone Pharmaceuticals, Inc.
650-358-3437


SOURCE: SciClone Pharmaceuticals, Inc.

[tupper]

Da wäre doch mal wieder ein ordentlicher Schub fällig!

Wofür kriegen die eigentlich die 8 Mio?

[tupper]

Antwort auf Beitrag Nr.: 21.056.024 von tupper am 03.04.06 17:00:04

Heute gehts aber wieder zur Sache!!
Ne Verlustmeldung wäre vielleicht besser für den Kurs gewesen?
Onkelchen, was denkst du? Bist du noch drin?

[nkelchen]

Antwort auf Beitrag Nr.: 21.070.991 von tupper am 04.04.06 16:40:35

hallo Tupper,
bin noch mit 50%investiert.
Hatte bei 3,12 meine halbe Posi mit 50%Gewinn aufgelöst.
Gruss
nk

[tupper]

Hi Onkelchen!
Da kannst du ja in Ruhe abwarten, was kommt.
Ich hab meine noch alle. Die letzten beiden Tage dürften etliche rausgespült haben. - Naja, mal sehen!
Letztes Jahr war der Verlust 8 Mio. Mit den Zahlungen von Glaxo müssten die im 2. Quartal ja sogar schwarze Zahlen schreiben.

1. Quartal 2 Mio Verlust, spätestens Mai neue Ergebnisse. - Ich glaub, ich zocke noch ein bisschen!

[nkelchen]

Antwort auf Beitrag Nr.: 21.088.765 von tupper am 05.04.06 16:23:30

die 2,75 könnten der Boden gewesen sein.
SK 3,10 (Tageshoch)
und der 2wöchige downtrend scheint auch gebrochen.
mer mal....
Gruss
nk

[tupper]

Antwort auf Beitrag Nr.: 21.223.337 von nkelchen am 18.04.06 14:20:12

Es scheint,es könnte sein.
Und bei 2,30 lockt das Gap!
Da braucht`s schon eine Menge Mut zum Kaufen.
Indikatoren sehen aber schon ganz gut aus. Ich tippe mal auf eine Pendelbewegung um die 3 herum und somit Aufbau einer etwas stabileren Unterstützung.

Gruß
tupper

[nkelchen]

Antwort auf Beitrag Nr.: 21.226.773 von tupper am 18.04.06 17:06:28

Show Me All Trading News Revenue Revision BREAKING NEWS Coverage Reiterated Coverage Initiated ECONOMIC NEWS SMALL STOCK FOREX NEWS Downgrade Analyst Changes Market Analysis EUROPEAN MARKETS Dividend Earnings Estimate Change STOCK ALERT ASIAN MARKETS IMPORTANT WS EVENT TOP STORY
SciClone Names Friedhelm Blobel President, CEO, Director - Quick Facts

Monday, April 24, 2006; Posted: 06:45 AM


(RTTNews) - SciClone Pharmaceuticals, Inc. (SCLN | charts | news | PowerRating) revealed the appointment of Friedhelm Blobel as President, Chief Executive Officer and a Director of the Company effective as of June 2, 2006.

The company said that Ira Lawrence would continue as President and Chief Executive Officer until June 2, 2006, and after that date, would serve as a consultant to the company. Lawrence also would continue to serve as a Director of the company and would serve as a member of the Business Development Committee and the newly formed Science Review Committee of the Board of Directors. Lawrence's resignation was for personal reasons.

Copyright(c) 2006 RealTimeTraders.com, Inc. All Rights Reserved

[tupper]

Ein Non-Event meiner Meinung nach. Er bleibt ja dabei. Nehmen wir ihm die persönlichen Gründe mal ab.
Die Meldung über die deutlich verbesserte Impfwirkung gegen Tuberkulose hast du aber verpennt. Oder?

Show Me All Trading News Revenue Revision BREAKING NEWS Coverage Reiterated Coverage Initiated ECONOMIC NEWS SMALL STOCK FOREX NEWS Downgrade Analyst Changes Market Analysis EUROPEAN MARKETS Dividend Earnings Estimate Change STOCK ALERT ASIAN MARKETS IMPORTANT WS EVENT TOP STORY

Auf welcher Seite recherchierst du denn?

Gruß
tupper

[nkelchen]

Antwort auf Beitrag Nr.: 21.301.057 von tupper am 24.04.06 19:39:38

Interactivebrokers bietet einen Newsfeed von google und yahoo.
Da kommen dann immer die neuesten Meldungen rein.

Z.B.

http://www.marketwire.com/mw/release_html_b1?release_id=1245…
SciClone Pharmaceuticals Announces Appointment of New CEO
SAN MATEO, CA -- (MARKET WIRE) -- 04/24/2006 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment of Dr. Friedhelm Blobel as President, Chief Executive Officer and a Director of the Company effective as of June 2, 2006. Ira Lawrence, M.D. will continue as President and CEO until June 2, 2006, and after that date, will serve as a consultant to the Company. Dr. Lawrence also will continue to serve as a Director of the Company and will serve as a member of the Business Development Committee and the newly formed Science Review Committee of the Board of Directors. Dr. Lawrence's resignation was for personal reasons.

"Dr. Lawrence has led SciClone very effectively through a challenging time and positioned it well to capitalize on significant opportunities," said Dean S. Woodman, Chairman of the Board of Directors. "We deeply regret Ira's departure from the CEO position, and are delighted that he will stay with us on the Company's Board. We are very pleased that Dr. Blobel will be joining SciClone," he added. "His extensive pharmaceutical company management experience in Europe, Asia and the United States provides the global perspective so important to the refinement and execution of the SciClone business strategy."

"Friedhelm is a seasoned and knowledgeable leader who has an excellent background to lead SciClone forward," stated Dr. Lawrence. "I look forward to continuing to assist the Company as a board member and consultant, and regret that my personal situation does not allow me to continue as President and CEO. I believe the Company will be in good hands as we evaluate our opportunities and position the Company for future success."

Dr. Blobel noted, "I am pleased by the vote of confidence that the Board of Directors has given me and I look forward to the challenge of building upon the Company's strengths and positioning the Company for future success."

Dr. Blobel served most recently as President, CEO and a Director of Gryphon Therapeutics, Inc., a South San Francisco-based biopharmaceutical company. Prior to joining Gryphon in July 2000 Dr. Blobel spent more than 20 years as an executive with the Hoechst Group and the Boehringer Mannheim Group including many responsibilities in the areas of diabetes and in vitro diagnostics. His roles at these companies included Group President of several product divisions, Chief Technology Officer, General Manager in Tokyo, Japan of a marketing and sales joint venture between Boehringer and Yamanouchi Pharmaceuticals (now Astellas), Senior VP of R&D Diabetes and Patient Care in Mannheim, Germany as well as in Indianapolis, USA.

Dr. Blobel earned his doctorate degree ("Dr.rer.nat."; a Ph.D. equivalent) with a dissertation in Biochemistry and Microbiology from the University of Hohenheim, Germany and holds an advanced degree in Chemistry from the University of Stuttgart, Germany.

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN is currently being evaluated in late-stage clinical trials for the treatment of malignant melanoma and hepatitis C. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. SciClone's strategy is to leverage its advantage in China by in-licensing or acquiring the marketing rights to other products to market in this rapidly growing pharmaceutical market. SciClone's other drug development candidate is SCV-07, currently in early clinical development in the U.S. for the treatment of viral and other infectious diseases. For more information about SciClone, visit www.sciclone.com.






--------------------------------------------------------------------------------


Corporate Contact:
Becky Horner
Investor Relations
SciClone Pharmaceuticals, Inc.
650-358-3437


SOURCE: SciClone Pharmaceuticals, Inc.

[tupper]

Antwort auf Beitrag Nr.: 21.301.235 von nkelchen am 24.04.06 19:50:07

Das ist komfortabel! Danke!

Hab auch noch was für dich:

Scientists at Mycos Research evaluated three escalating doses of SCV-07 used in four different administration schedules to determine the optimal dose and treatment regimen. The highest protection against M. tuberculosis was observed in the animals that received SCV-07 both before and after vaccination, at an intermediate dose. Animals given SCV-07 prior to TB vaccination demonstrated a better response than those given SCV-07 only after TB vaccination.

"These data suggest that SCV-07 primes the cellular immune response, so that, with subsequent TB vaccination the immune system is able to mount a stronger defense against the infection than it could with the vaccine alone," commented Dr. Cynthia Tuthill, Chief Scientific Officer and Senior Vice President of Scientific Affairs at SciClone Pharmaceuticals, Inc. "Furthermore, these findings suggest that SCV-07 could be valuable in other vaccine settings; for instance, the addition of SCV-07 could allow individuals to receive a lower quantity of a vaccine while still achieving effective protection against viral or bacterial infections."

Da steht noch ein bisschen mehr dabei, aber ich wollte nicht alles zumüllen.

[tupper]

Q1/06: 2,4 Mio Verlust
Q2/06: mindestens 5 Mio Gewinn
Breakeven in 2006

Wann kommt die Gegenreaktion?

[nort.]

[nkelchen]

Restposi verscherbelt -
tschüss und viel Glück noch..
nk